Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Ning Xie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4628-2299; OpenAlex author ID A5100746429. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. ARHGAP11A is a potential prognostic biomarker and therapeutic target for pancreatic adenocarcinoma. Last author DOI 10.1016/j.biocel.2025.106804↗
  2. TOB1 suppresses proliferation in K-Ras wild-type pancreatic cancer. Co-author DOI 10.1002/cam4.2756↗
  3. Dysbindin promotes pancreatic ductal adenocarcinoma metastasis by activating NF-κB/MDM2 via miR-342-3p. Co-author DOI 10.1016/j.canlet.2020.02.033↗
  4. Identification of Upregulated HNRNPs Associated with Poor Prognosis in Pancreatic Cancer. First author DOI 10.1155/2019/5134050↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiu-ai Shu · 1 shared paper, 2025 · strength 0.25
  2. Yuru Bai · 2 shared papers, 2019–2020 · strength 0.22
  3. Lu Qiao · 2 shared papers, 2019–2020 · strength 0.22
  4. Na Liu · 1 shared paper, 2020 · strength 0.11
  5. Na Liu · 1 shared paper, 2019 · strength 0.11
  6. Dinghuang Zhu · 1 shared paper, 2020 · strength 0.10
  7. Xin Guo · 1 shared paper, 2020 · strength 0.10
  8. Yong Chen · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.